medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2017-10-65-68medsovet-1869Research ArticleДЕМИЕЛИНИЗИРУЮЩИЕ ЗАБОЛЕВАНИЯDEMYELINATING DISEASESМОНОКЛОНАЛЬНЫЕ АНТИТЕЛА В ТЕРАПИИ РАССЕЯННОГО СКЛЕРОЗАMONOCLONAL ANTIBODY FOR MULTIPLE SCLEROSIS TREATMENTПоповаЕ. В.PopovaE. V.

Кандидат медицинских наук.

Москва

Ph.D. in medicine.

Moscow

Российский национальный исследовательский медицинский университет им. Н.И. ПироговаРоссияPirogov Russian National Research Medical UniversityRussian Federation2017250520170106568Copyright © Попова Е.В., 20172017Попова Е.В.Popova E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1869

Моноклональные антитела используются довольно широко в разных областях современной медицины, например в онкологии, ревматологии, гастроэнтерологии, трансплантологии. Более 10 лет моноклональные  антитела стали исследоваться для лечения рассеянного склероза (РС) и внедряться в патогенетическую терапию РС. Обсуждаются клинические исследования уже зарегистрированных моноклональных антител на территории РФ, таких как натализумаб  и алемтузумаб.

Monoclonal antibodies are widely used in various fields of modern medicine, for example, in oncology, rheumatology, gastroenterology, transplantation. Since beginning of this century monoclonal antibodies began to be explored for the treatment of multiple sclerosis (MS). From this period monoclonal antibody also actively introduced in pathogenetic therapy of MS. In this review, we discuss the findings of clinical trials already registered monoclonal antibodies in the Russian Federation, such as Natalizumab and Alemtuzumab.

рассеянный склерозпрепаратыизменяющие течение рассеянного склерозамоноклональные антителанатализумабалемтузумабdisseminated sclerosisdrugs changing the course of DS (DCCDS)monoclonal antibodiesNatalizumabAlemtuzumabReferencesPolman C, O’Connor P, Havrdova E et al. A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2006, 354(9): 899-910. doi: 10.1056/nejmoa044397.Polman C, O’Connor P, Havrdova E et al. A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2006, 354(9): 899-910. doi: 10.1056/nejmoa044397.Rudick R, Stuart W, Calabresi P et al. Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2006, 354(9): 911-923. doi: 10.1056/nejmoa044396.Rudick R, Stuart W, Calabresi P et al. Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2006, 354(9): 911-923. doi: 10.1056/nejmoa044396.Инструкция по применению препарата натализумаб 2015 г., регистрационный номер ЛСР-008582/10.Инструкция по применению препарата натализумаб 2015 г., регистрационный номер ЛСР-008582/10.Dahlhaus S, Hoepner R, Chan A et al. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84(10): 1068-1074. doi: 10.1136/jnnp-2013-304897.Dahlhaus S, Hoepner R, Chan A et al. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84(10): 1068-1074. doi: 10.1136/jnnp-2013-304897.Kerbrat A, Le Page E, Leray E et al. Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients. Journal of the Neurological Sciences, 2011, 308(1-2): 98-102. doi: 10.1016/j.jns.2011.05.043.Kerbrat A, Le Page E, Leray E et al. Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients. Journal of the Neurological Sciences, 2011, 308(1-2): 98-102. doi: 10.1016/j.jns.2011.05.043.West T, Cree B. Natalizumab dosage suspension: Are we helping or hurting? Annals of Neurology, 2010, 68(3): 395-399. doi: 10.1002/ana.22163.West T, Cree B. Natalizumab dosage suspension: Are we helping or hurting? Annals of Neurology, 2010, 68(3): 395-399. doi: 10.1002/ana.22163.Killestein J, Vennegoor A, Strijbis E et al. Natalizumab drug holiday in multiple sclerosis: Poorly Tolerated. Annals of Neurology, 2010, 68(3): 392-395. doi: 10.1002/ana.22074.Killestein J, Vennegoor A, Strijbis E et al. Natalizumab drug holiday in multiple sclerosis: Poorly Tolerated. Annals of Neurology, 2010, 68(3): 392-395. doi: 10.1002/ana.22074.O’Connor P, Goodman A, Kappos L et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology, 2011, 76(22): 1858-1865. doi: 10.1212/wnl.0b013e31821e7c8a.O’Connor P, Goodman A, Kappos L et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology, 2011, 76(22): 1858-1865. doi: 10.1212/wnl.0b013e31821e7c8a.Kleinschmidt-DeMasters B, Miravalle A, Schowinsky J, Corboy J, Vollmer T. Update on PML and PML-IRIS Occurring in Multiple Sclerosis Patients Treated With Natalizumab. Journal of Neuropathology & Experimental Neurology, 2012, 71(7): 604-617. doi: 10.1097/nen.0b013e31825caf2c.Kleinschmidt-DeMasters B, Miravalle A, Schowinsky J, Corboy J, Vollmer T. Update on PML and PML-IRIS Occurring in Multiple Sclerosis Patients Treated With Natalizumab. Journal of Neuropathology & Experimental Neurology, 2012, 71(7): 604-617. doi: 10.1097/nen.0b013e31825caf2c.Freedman M. Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis. Journal of Clinical & Cellular Immunology, 2013, 04(04). doi: 10.4172/2155-9899.1000152.Freedman M. Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis. Journal of Clinical & Cellular Immunology, 2013, 04(04). doi: 10.4172/2155-9899.1000152.Hassoun L, Eisele J, Thomas K, Ziemssen T. Hands on Alemtuzumab-experience from clinical practice: whom and how to treat. Multiple Sclerosis and Demyelinating Disorders, 2016, 1(1). doi: 10.1186/s40893-016-0011-1.Hassoun L, Eisele J, Thomas K, Ziemssen T. Hands on Alemtuzumab-experience from clinical practice: whom and how to treat. Multiple Sclerosis and Demyelinating Disorders, 2016, 1(1). doi: 10.1186/s40893-016-0011-1.Moreau T, Scolding N, Compston A et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. The Lancet, 1994, 344(8918): 298-301. doi: 10.1016/s0140-6736(94)91339-0.Moreau T, Scolding N, Compston A et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. The Lancet, 1994, 344(8918): 298-301. doi: 10.1016/s0140-6736(94)91339-0.Coles A, Wing M, Molyneux P et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Annals of Neurology, 1999, 46(3): 296-304. doi: 10.1002/1531-8249(199909)46:3<296::aid-ana4>3.0.co,2-#.Coles A, Wing M, Molyneux P et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Annals of Neurology, 1999, 46(3): 296-304. doi: 10.1002/1531-8249(199909)46:3<296::aid-ana4>3.0.co,2-#.Paolillo A, Coles A, Molyneux P et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology, 1999, 53(4): 751-751. doi: 10.1212/wnl.53.4.751.Paolillo A, Coles A, Molyneux P et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology, 1999, 53(4): 751-751. doi: 10.1212/wnl.53.4.751.Montalban X, Inshasi J, Coles A et al. Efficacy and safety of Alemtuzumab in treatment-naive patients with relapsing-remitting multiple sclerosis: Four-year follow-up of the Care-MS I study. Multiple Sclerosis and Related Disorders, 2014, 3(6): 761-762. doi: 10.1016/j.msard.2014.09.207.Montalban X, Inshasi J, Coles A et al. Efficacy and safety of Alemtuzumab in treatment-naive patients with relapsing-remitting multiple sclerosis: Four-year follow-up of the Care-MS I study. Multiple Sclerosis and Related Disorders, 2014, 3(6): 761-762. doi: 10.1016/j.msard.2014.09.207.Kieseier B, Sahraian M, Coles A et al. Efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: Four-year follow-up of the Care-MS II study. Multiple Sclerosis and Related Disorders, 2014, 3(6): 756. doi: 10.1016/j.msard.2014.09.194.Kieseier B, Sahraian M, Coles A et al. Efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: Four-year follow-up of the Care-MS II study. Multiple Sclerosis and Related Disorders, 2014, 3(6): 756. doi: 10.1016/j.msard.2014.09.194.Хасаева М., Горохова Т., Бойко А., Гусев Е. Алемтузумаб – новый препарат на основе моноклональных антител для лечения рассеянного склероза: терапевтические возможности и риски (обзор). Журн. неврологии и психиатрии, 2013, 113: 87-92.Хасаева М., Горохова Т., Бойко А., Гусев Е. Алемтузумаб – новый препарат на основе моноклональных антител для лечения рассеянного склероза: терапевтические возможности и риски (обзор). Журн. неврологии и психиатрии, 2013, 113: 87-92.Coles A, Fox E, Vladic A et al. Alemtuzumab more effective than interferon -1a at 5-year follow-up of CAMMS223 Clinical Trial. Neurology, 2012, 78(14): 1069-1078. doi: 10.1212/wnl.0b013e31824e8ee7.Coles A, Fox E, Vladic A et al. Alemtuzumab more effective than interferon -1a at 5-year follow-up of CAMMS223 Clinical Trial. Neurology, 2012, 78(14): 1069-1078. doi: 10.1212/wnl.0b013e31824e8ee7.Perumal J.Khan O. Emerging Disease-Modifying Therapies in Multiple Sclerosis. Current Treatment Options in Neurology, 2012, 14(3): 256-263. doi: 10.1007/s11940-012-0173-x.Perumal J.Khan O. Emerging Disease-Modifying Therapies in Multiple Sclerosis. Current Treatment Options in Neurology, 2012, 14(3): 256-263. doi: 10.1007/s11940-012-0173-x.Cossburn M, Pace A, Jones J et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology, 2011, 77(6): 573-579. doi: 10.1212/wnl.0b013e318228bec5.Cossburn M, Pace A, Jones J et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology, 2011, 77(6): 573-579. doi: 10.1212/wnl.0b013e318228bec5.Alireza M, J Steven A, Mohammad Ali S, Robert Z. Alemtuzumab and multiple sclerosis: therapeutic application. Expert Opinion on Biological Therapy, 2010, 10(3): 421-429. doi: 10.1517/14712591003586806.Alireza M, J Steven A, Mohammad Ali S, Robert Z. Alemtuzumab and multiple sclerosis: therapeutic application. Expert Opinion on Biological Therapy, 2010, 10(3): 421-429. doi: 10.1517/14712591003586806.Клинические рекомендации по применению препарата алемтузумаб (Лемтрада), 2017. https: //www.ructrims.org/files/ructrims_org_recomend_alemtuzumab.pdf.Клинические рекомендации по применению препарата алемтузумаб (Лемтрада), 2017. https: //www.ructrims.org/files/ructrims_org_recomend_alemtuzumab.pdf.Инструкция по применению препарата Лемтрада 2016 г.Инструкция по применению препарата Лемтрада 2016 г.

The authors declare that there are no conflicts of interest present.